more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$68.12 USD

+1.62 (2.44%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $68.12 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

Top 32% (80 out of 251)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Rides on Innovation Amid Rising Costs

by Zacks Equity Research Published on December 20,2022

Edwards Lifesciences (EW) expects to report underlying sales growth in the mid-single-digit range for 2022, banking on market growth and the adoption of premium technologies.

medical

Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options

by Zacks Equity Research Published on December 16,2022

Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.

EWPositive Net Change

medical

Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise

by Zacks Equity Research Published on October 28,2022

Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.

Edwards Lifesciences (EW) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research Published on October 27,2022

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.61% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on October 20,2022

Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research Published on October 19,2022

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intuitive Surgical, Inc. (ISRG) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research Published on October 18,2022

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 8.18% and 2.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

by Zacks Equity Research Published on October 18,2022

Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.

Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues

by Zacks Equity Research Published on October 07,2022

Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.

medical

Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve

by Zacks Equity Research Published on September 13,2022

Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.

Edward Lifesciences (EW) Gains From New Products Amid Cost Woe

by Zacks Equity Research Published on September 07,2022

Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.

OCPNY or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on September 06,2022

OCPNY vs. EW: Which Stock Is the Better Value Option?

Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision

by Zacks Equity Research Published on August 18,2022

Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.

Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up

by Zacks Equity Research Published on July 29,2022

Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.

Edwards Lifesciences (EW) Matches Q2 Earnings Estimates

by Zacks Equity Research Published on July 28,2022

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research Published on July 25,2022

Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.